In addition, known mutations in KDELR1 and KDELR2 are associated with lymphopenia and osteogenesis imperfecta, respectively, making KDEL receptor replacement an attractive therapeutic strategy for these conditions [87,88]. The gene discussed is KDELR2; the disease is lymphopenia.